Cogent Biosciences
COGT
112 hedge funds and large institutions have $633M invested in Cogent Biosciences in 2022 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 43 increasing their positions, 19 reducing their positions, and 13 closing their positions.
208% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 13
126% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 19
81% more capital invested
Capital invested by funds: $349M → $633M (+$284M)
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
29% more funds holding
Funds holding: 87 → 112 (+25)
7.24% more ownership
Funds ownership: 103.08% → 110.32% (+7.2%)
10% less call options, than puts
Call options by funds: $2.12M | Put options by funds: $2.35M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$29.2M |
| 2 |
VA
VR Adviser
New York
|
+$20.1M |
| 3 |
CC
Commodore Capital
New York
|
+$9.86M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.37M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$8.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$7.06M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.39M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$5.46M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$3.81M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$3.43M |
COGT Hedge Fund Activity: Q2 2022 in Review
112 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q2 2022, worth a combined $633M — up 81% from $349M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new COGT positions and 13 closed out — a net gain of 27 holders — while 43 added to existing stakes and 19 trimmed.
The largest buyer was Deerfield Management, adding an estimated $29.2M. The largest seller was Janus Henderson Group, cutting an estimated $7.06M.
- 112 institutional investors held Cogent Biosciences (COGT) as of Q2 2022, up from 87 in Q1 2022.
- Funds reported $633M of Cogent Biosciences stock for Q2 2022, up 81% quarter-over-quarter.
- 40 funds opened new Cogent Biosciences positions in Q2 2022 and 13 closed out, a net change of +27 holders.
- The largest Cogent Biosciences buyer in Q2 2022 was Deerfield Management, an estimated $29.2M added.
- The largest Cogent Biosciences seller in Q2 2022 was Janus Henderson Group, an estimated $7.06M sold.
Based on aggregated 13F filings for Q2 2022.